6.4 New coronavirus pneumonia
At present, COVID-19 is still rampant in many countries around the world
and cannot be effectively controlled. Xia[75] et
al. Combined with network pharmacology and molecular docking, found that
the Lianhua Qingwen capsule (LQC) has a certain curative effect in
patients with COVID-19, and AKT1 may be the therapeutic target of
COVID-19. Tao[76] and others, through network
pharmacology, revealed that baicalein and quercetin may play a
therapeutic role in COVID-19 by regulating a variety of signaling
pathways through ACE2. In addition, Liu [77] et
al. Screened new candidate drugs for the treatment of COVID-19 based on
network pharmacology and transcriptomics methods, and identified 18
separate candidate drugs after screening and analysis, including drugs
not previously proposed for the treatment of COVID-19, such as
nicardipine, planting, tibial and promethazine.